1. Home
  2. LFVN vs RLYB Comparison

LFVN vs RLYB Comparison

Compare LFVN & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifevantage Corporation (Delaware)

LFVN

Lifevantage Corporation (Delaware)

HOLD

Current Price

$6.24

Market Cap

78.0M

Sector

Health Care

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.80

Market Cap

89.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFVN
RLYB
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.0M
89.2M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
LFVN
RLYB
Price
$6.24
$16.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
★ $11.00
N/A
AVG Volume (30 Days)
★ 46.4K
7.3K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
★ 3.56%
N/A
EPS Growth
N/A
★ N/A
EPS
0.40
★ 6.16
Revenue
★ $203,204,000.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.73
★ $2.70
Revenue Growth
1.86
★ 43.00
52 Week Low
$3.90
$0.48
52 Week High
$11.71
$17.57

Technical Indicators

Market Signals
Indicator
LFVN
RLYB
Relative Strength Index (RSI) 46.57 46.15
Support Level $6.12 $16.49
Resistance Level $6.78 $17.30
Average True Range (ATR) 0.30 0.38
MACD 0.01 -0.06
Stochastic Oscillator 33.77 22.78

Price Performance

Historical Comparison
LFVN
RLYB

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: